Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation
Section snippets
Methods
The Local Ethical Committee approved this investigation.
Results
Overall, 213 patients received their first HTx at our institution during the study period. We excluded 4 patients who underwent re-HTx, 31 who died during the first year after HTx, 5 whose CMV sampling was inadequate, and 7 without angiographic studies due to vascular access problems. Thus, we finally included 166 HTx recipients.
Table 1 describes the main baseline characteristics of the cohort. Most patients received induction therapy with OKT3 and triple therapy with cyclosporine,
Discussion
Our study shows that CMV infection, including asymptomatic replication, is an independent risk factor associated with the development of CAV.
We were able to demonstrate it through a special scenario that occurred during the interval we chose for the study: a homogeneous cohort who received intense immunosuppressive therapy, a short course of intravenous ganciclovir prophylaxis, standardized blood sampling to search for CMV replication, and a long-term angiographic follow-up. Of course, our
Disclosure statement
None of the authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose.
The authors are grateful to David Lora-Pablos (Research Institute, Clinical Research Unit, University Hospital 12 de Octubre) for the statistical analyses and to Martin J. Smyth, BA, for revision of the English version of this manuscript.
This study was partially supported by the Spanish Cardiovascular Research
References (40)
- et al.
The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012
J Heart Lung Transplant
(2012) - et al.
International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010
J Heart Lung Transplant
(2010) - et al.
revalence and prognostic value of cardiac allograft vasculopathy 1 year after heart transplantation according to the ISHLT recommended nomenclature
J Heart Lung Transplant
(2012) - et al.
A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients
J Heart Lung Transplant
(2011) - et al.
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection
J Heart Lung Transplant
(2005) - et al.
Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years
J Am Coll Cardiol
(2005) The role of viruses in cardiac allograft vasculopathy
Am J Transplant
(2004)- et al.
Cytomegalovirus antigen within human arterial smooth muscle cells
Lancet
(1983) - et al.
Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease?
J Clin Virol
(2006) - et al.
Lower incidence of liver graft rejection in patients on diltiazem plus cyclosporine therapy
Transplant Proc
(1998)
An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy
Am J Cardiol
Cardiac allograft vasculopathy: recent developments
Circulation
Indirect effects of cytomegalovirus infection in solid organ transplant recipients
Enferm Infecc Microbiol Clin
Factors associated with the development of cardiac allograft vasculopathy—a systematic review of observational studies
Clin Transplant
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration
Epidemiology
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation
Transplantation
Prevention and treatment of coronary artery vasculopathy
Curr Opin Organ Transplant
Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease
Transplantation
Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients
J Infect Dis
Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study
Transplantation
Cited by (67)
Infections in Heart and Lung Transplant Recipients
2024, Infectious Disease Clinics of North AmericaCytomegalovirus infection is associated with impaired myocardial flow reserve after heart transplantation
2024, Journal of Heart and Lung TransplantationReview of Postoperative Care for Heart Transplant Recipients
2023, Journal of Cardiothoracic and Vascular AnesthesiaCardiac allograft vasculopathy after heart transplantation: Pathophysiology, detection approaches, prevention, and treatment management
2022, Trends in Cardiovascular MedicineRole of cytomegalovirus infection after kidney transplantation on the subsequent risk of atherosclerotic and thrombotic events
2022, Atherosclerosis PlusCitation Excerpt :Regarding viral kinetics, no differences were found in the CMV-AUCs (Fig. S3d) or peak CMV viral load (Fig. S4d) through the first 180 days after transplantation according to the subsequent occurrence of PTE. The development of CMV infection after SOT has been linked to atherosclerotic and thrombotic events as part of the so-called “indirect effects” attributed to this pathogen [19,31,32]. Such deleterious effects are presumably derived from immune and non-immune actions that induce endothelial cell injury, chronic inflammation and a hypercoagulable state [33,34].
Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients
2022, American Journal of Transplantation